Call for branded drugs to be phased out in India

8 May 2017
drugs_pills_tablets_big

Doctors and public health groups in India have come up with the suggestion that the government should work for the gradual phasing out of branded drugs in a calibrated manner along with the abolition of differential pricing under different brands to give a push to generic drug prescriptions, noted Brand India Pharma, an initiative led by Pharmexcil (Pharmaceutical Export Promotion Council) and IBEF (India Brand Equity Foundation) under the aegis of the Department of Commerce.

Prime Minister Narendra Modi had recently announced that the government was looking at a legal framework ensuring mandatory prescription of low cost generic medicines by doctors. Following the announcement, the Medical Council of India has stated that doctors should only prescribe generic medicines.

The proposal for mandatory prescription of generic medicines would, however, be useless and counterproductive if it is carried out as a stand-alone measure, according to the All India Drug Action Network (AIDAN). Phasing out of the branded drugs should be done gradually so that not only the doctors but also pharmacists are not able to promote specific brands.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics